Regentis Biomaterials
Manufacturing · Israel · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Medinat Hyahudim 60 Herzlia Pituach, Her...Phone Number
+972 99601917Website
www.regentis.co.ilRevenue
-Stock Symbol
RGNTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Regentis Biomaterials
Regentis Biomaterials is a tissue repair company focused on developing and commercializing an innovative hydrogel platform for the repair of damaged tissue. The companys current efforts are focused on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue. Regentis Biomaterials is a privately held company with offices in Princeton, New Jersey and Or Akiva, Israel.Explore more
Regentis Biomaterials Org Chart
AG
Chief Financial Officer
GR
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Regentis Biomaterials your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Regentis Biomaterials recently announced quarterly report
Product Launch: Get notified when Regentis Biomaterials launches new products
Check out if Regentis Biomaterials is spiking on competitors!
Funding: Get notified immidiatlly once Regentis Biomaterials has new funding data
Click to see if Regentis Biomaterials had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Regentis Biomaterials
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Regentis Biomaterials, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Regentis Biomaterials has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Regentis Biomaterials
Find 3 more new buyers
Company Profile Activity
Activity Insights
Regentis Biomaterials is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Regentis Biomaterials is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Regentis Biomaterials.
Regentis Biomaterials financials insights
Gather financial insights about Regentis Biomaterials, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series B
$7.5M
2012
Series C
$10M
2016
Series D
$15M
2026
Stock/Share Issuance
$6.5M
Regentis Biomaterials Tech Stack
A closer look at the technologies used by Regentis Biomaterials
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Initial Public Offering (IPO)
IPO, Finance
Regentis Biomaterials News & Media
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business ...
ACCESS Newswire Press Release.Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering
Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate grosRegentis Biomaterials Ltd. Announces Pricing of Initial Public Offering
Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at an initial public offering price of $8.00 per Ordinary Share, for aggreRegentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.
NEW YORK & OR-AKIVA, Israel--(BUSINESS WIRE)--OceanTech Acquisitions I Corp., a Delaware corporation (NASDAQ: OTEC, OTECU, OTECW) ("OceanTech"), a publicly-traded special purpose acquisition company, today announced the execution of a definitive Agreement and Plan of Merger (the “Merger Agreement”) with Regentis Biomaterials Ltd, an Israeli company (“Regentis”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Regentis Biomaterials
Sign Up For FreeTo access detailed company insights
Regentis Biomaterials is a tissue repair company focused on developing and commercializing an innovative hydrogel platform for the repair of damaged tissue. The companys current efforts are focused on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue. Regentis Biomaterials is a privately held company... Read More
